Model-Based Analysis of In Vivo Release Data of Levonorgestrel Implants: Projecting Long-Term Systemic Exposure
Open Access
- 2 May 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1393
Abstract
Levonorgestrel (LNG) is a progestin used in many contraceptive formulations, including subcutaneous implants. There is an unmet need for developing long-acting formulations for LNG. To develop long-acting formulations, release functions need to be investigated for LNG implant. Therefore, a release model was developed and integrated into an LNG physiologically-based pharmacokinetic (PBPK) model. Utilizing a previously developed LNG PBPK model, subcutaneous administration of 150 mg LNG was implemented into the modeling framework. To mimic LNG release, ten functions incorporating formulation-specific mechanisms were explored. Release kinetic parameters and bioavailability were optimized using Jadelle® clinical trial data (n = 321) and verified using two additional clinical trials (n = 216). The First-order release and Biexponential release models showed the best fit with observed data, the adjusted R-squared (R2) value is 0.9170. The maximum released amount is approximately 50% of the loaded dose and the release rate is 0.0009 per day. The Biexponential model also showed good agreement with the data (adjusted R2 = 0.9113). Both models could recapitulate observed plasma concentrations after integration into the PBPK simulations. First-order and Biexponential release functionality may be useful in modeling subcutaneous LNG implants. The developed model captures central tendency of the observed data as well as variability of release kinetics. Future work focuses on incorporating various clinical scenarios into model simulations, including drug-drug interactions and a range of BMIs.Keywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1185454)
This publication has 9 references indexed in Scilit:
- Determining the Exposure Threshold for Levonorgestrel Efficacy Using an Integrated Model Based Meta‐Analysis ApproachClinical Pharmacology & Therapeutics, 2021
- Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug‐Drug Interactions Using Physiologically Based Pharmacokinetic ModelingCPT: Pharmacometrics & Systems Pharmacology, 2020
- Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and levonorgestrel-containing contraceptives with oral or subdermal administration routeThe European Journal of Contraception & Reproductive Health Care, 2020
- Levonorgestrel release rates measured through analysis of two-rod contraceptive explantsContraception: X, 2020
- Randomized trial to evaluate contraceptive efficacy, safety and acceptability of a two-rod contraceptive implant over 4 years in the Dominican RepublicContraception: X, 2019
- Generating Model Integrated Evidence for Generic Drug Development and AssessmentClinical Pharmacology & Therapeutics, 2018
- In vivo release of levonorgestrel from Sino-implant (II) — an innovative comparison of explant dataContraception, 2015
- Kinetic modeling on drug release from controlled drug delivery systems.2010
- Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implantsContraception, 1997